Neurocrine Biosciences, Inc.

NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.

zacks.com - 2026-07-15 16:00:16

Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

zacks.com - 2026-07-14 13:21:03

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

zacks.com - 2026-07-10 13:46:04

Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.

fxempire.com - 2026-07-10 11:58:48

Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.

prnewswire.com - 2026-07-09 16:01:00

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

247wallst.com - 2026-07-09 13:29:39

Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

zacks.com - 2026-07-08 13:01:09

NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.

zacks.com - 2026-07-06 11:45:53

Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.

seekingalpha.com - 2026-07-02 14:55:01

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.

prnewswire.com - 2026-07-01 16:05:00

Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-01 13:01:09

NBIX, MYRG, XYZ, DK and DY show strong relative price strength, upbeat estimate revisions and solid fundamentals heading into the second half.

zacks.com - 2026-07-01 09:11:05

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

zacks.com - 2026-06-24 13:45:58

NBIX, ILPT and CASY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24th, 2026.

zacks.com - 2026-06-24 11:01:19

BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.

zacks.com - 2026-06-24 05:06:05

NVGS, BY and NBIX made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 24th, 2026.

zacks.com - 2026-06-24 04:36:13

Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History Study SAN DIEGO, June 15, 2026 /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms characteristic of Prader-Willi syndrome (PWS).   "These compelling data further reinforce our confidence in VYKAT XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome," said Sanjay Keswani, M.D.

prnewswire.com - 2026-06-15 16:10:00

Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone Nearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugs Findings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITY SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 11β‑hydroxylase deficiency. This subtype was not previously studied in clinical trials of CRENESSITY® (crinecerfont) and is the second most common form of classic CAH after 21-hydroxylase deficiency, accounting for approximately 5% of cases.

prnewswire.com - 2026-06-15 16:05:00

Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver survey data showed universal satisfaction with CRENESSITY, willingness to recommend treatment and increased optimism about their child's future quality of life following treatment initiation SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Patients with advanced bone age at baseline experienced slowed bone age progression and improved predicted adult height after two years of treatment.

prnewswire.com - 2026-06-15 08:35:00

Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved >5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient‑reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well‑being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with CRENESSITY SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years of treatment with CRENESSITY® (crinecerfont) for classic congenital adrenal hyperplasia. These results, together with additional presentations highlighting improvement in bone outcomes and patient-reported quality of life survey outcomes, were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.

prnewswire.com - 2026-06-15 08:30:00

Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 15:52:10

New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter 2 (VMAT2) inhibitor to demonstrate clinical remission in clinical trials A separate claims analysis indicates high prevalence of hepatic risk factors among patients with tardive dyskinesia; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment Together, these data add to a growing body of evidence supporting the potential of INGREZZA to provide clinically meaningful therapeutic benefits to a wide range of patients with tardive dyskinesia SAN DIEGO, June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT® 4 clinical trial demonstrating that adults with tardive dyskinesia (TD) treated with INGREZZA® (valbenazine) capsules experienced clinically meaningful and robust improvements in involuntary movement severity, including those who did not meet the stringent symptomatic remission threshold. These results, together with findings from a large retrospective Medicare claims analysis evaluating hepatic risk factors among patients newly diagnosed with TD, were presented at the 2026 Psych Congress Elevate in Las Vegas.

prnewswire.com - 2026-06-08 16:05:00

Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within 4 weeks  Clinician-reported data showed improvements in key aspects of daily life following INGREZZA treatment in nearly all patients with tardive dyskinesia and intellectual and developmental disabilities who had impaired function SAN DIEGO, June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity, as well as improvements in overall functional status, including physical and socio-emotional outcomes, with INGREZZA® (valbenazine) capsules. The findings were presented at the American Academy of Developmental Medicine and Dentistry's 24th Annual Education Conference in Dallas.

prnewswire.com - 2026-06-08 08:30:00

Neurocrine Biosciences to Present New Two‑Year CRENESSITY (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at EN

gurufocus.com - 2026-06-03 09:00:00

Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care continuum New data demonstrate the effect of CRENESSITY on long-term androgen control and glucocorticoid dose reduction and associated clinical outcomes Data from cross-sectional surveys highlight patient- and caregiver-reported quality of life improvements Case series highlights use of CRENESSITY in patients with classic CAH due to 11β‑hydroxylase deficiency Additional ENDO 2026 presentations include VYKAT™ XR (diazoxide choline) extended-release tablets data in hyperphagia associated with Prader-Willi syndrome (PWS), including late-breaking long-term extension findings following randomized withdrawal, and data evaluating sustained improvements in hyperphagia and behavioral symptoms through three years SAN DIEGO, June 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with CRENESSITY® (crinecerfont) in adult and pediatric populations with classic congenital adrenal hyperplasia. These data will be presented at the Endocrine Society's annual meeting, ENDO 2026, taking place from June 13-16, in Chicago.

prnewswire.com - 2026-06-03 08:30:00

Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript

seekingalpha.com - 2026-06-02 13:51:52

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annual Growth Stock Conference. Fireside chat on Tuesday, June 2, 2026 at 10:40 AM CT (11:40 AM ET) in Chicago Goldman Sachs 47 th Annual Global Healthcare Conference 2026.

prnewswire.com - 2026-05-26 16:01:00

Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social or physical impairment Following initiation of INGREZZA, 96% of patients with mild tardive dyskinesia showed clinician-reported improvement in uncontrolled movements; of those patients, 86% improved within 4 weeks Reductions in involuntary movements with INGREZZA treatment were associated with improvements in overall functional status, independence, activities of daily living and ability to work SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia (TD) severity and the impact of treatment with INGREZZA® (valbenazine) capsules in a real-world setting. In a subgroup analysis, nearly all patients with clinician-reported mild TD treated with INGREZZA experienced fewer uncontrolled movements, with most demonstrating symptom improvement within four weeks.

prnewswire.com - 2026-05-18 16:05:00

Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's first-in-class commercial portfolio alongside INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont).

prnewswire.com - 2026-05-18 08:46:00

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period.

globenewswire.com - 2026-05-14 07:00:00

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 19:50:45

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

zacks.com - 2026-05-07 13:45:21

Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance.

seekingalpha.com - 2026-05-06 18:24:54

New algorithms developed by expert clinical endocrinologists provide clear, practical recommendations for healthcare providers to reduce supraphysiologic glucocorticoid (GC) doses in patients with classic congenital adrenal hyperplasia (CAH) after starting CRENESSITY CRENESSITY reduces excess androgen production, enabling patients with classic CAH to move toward more physiologic GC dosing while maintaining essential daily cortisol replacement SAN DIEGO, May 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Published in The Journal of Clinical Endocrinology & Metabolism, the recommendations address a critical unmet need as real-world use of CRENESSITY expands in both pediatric and adult patients.

prnewswire.com - 2026-05-06 08:30:00

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-05 22:31:15

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-05 18:30:26

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $0.08 per share a year ago.

zacks.com - 2026-05-05 18:16:16

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. "Neurocrine's strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas," said Kyle W.

prnewswire.com - 2026-05-05 16:01:00

BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

globenewswire.com - 2026-05-05 14:33:06

SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern Time) on May 12, 2026 in Las Vegas.

prnewswire.com - 2026-05-05 09:00:00

Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due to untreated involuntary movements1 Respondents also reported missing an average of 8 hours of work or school per week due to tardive dyskinesia prior to treatment1 Findings released during Tardive Dyskinesia Awareness Week SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to school, volunteer or actively look for employment. About one in five surveyed working adults with TD reported quitting their job due to TD symptoms prior to treatment.1 Findings are released in recognition of Tardive Dyskinesia Awareness Week (May 3-9) to underscore the importance of increased awareness, early recognition and appropriate management of TD.

prnewswire.com - 2026-05-04 08:30:00

NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'2118 in adult participants. NBIP-'2118 is an investigational corticotropin-releasing factor type 2 receptor (CRF2) peptide agonist and a potential first-in-class therapy for obesity.

prnewswire.com - 2026-05-04 07:30:00

At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no longer insulin resistant Improved outcomes associated with excess androgens, including acne and androstenedione-to-testosterone ratio were also observed CRENESSITY delivered sustained reductions in adrenocorticotropic hormone and 17-hydroxyprogesterone, while enabling lower, more physiologic glucocorticoid dosing SAN DIEGO, May 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst® Pediatric study demonstrating durable androgen control, sustained decreases in glucocorticoid (GC) doses and meaningful improvements in clinical outcomes associated with excess androgens and long-term GC exposure in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont). Consistent with these findings, patients with classic congenital adrenal hyperplasia (CAH) continued to experience substantial reductions in adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) while achieving lower, more physiologic GC doses.

prnewswire.com - 2026-05-01 16:05:00

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:06:24

Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN DIEGO, April 29, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry demonstrating how the Tardive Dyskinesia Impact Scale helps characterize patient-reported burden in tardive dyskinesia and has been used in clinical studies to assess meaningful improvement over the course of treatment with INGREZZA® (valbenazine) capsules. The article builds on the original validation of the Tardive Dyskinesia Impact Scale (TDIS™) by defining what meaningful improvement means and how TDIS results should be interpreted in clinical trials.

prnewswire.com - 2026-04-29 16:05:00

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:06:57

Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen control Findings reinforce durable efficacy and a favorable long‑term safety profile in largest interventional trial to date conducted in classic congenital adrenal hyperplasia SAN DIEGO, April 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont), with approximately 70% of patients achieving GC doses within the physiologic range. These data build upon previously reported one-year results and were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas.

prnewswire.com - 2026-04-22 16:05:00

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

zacks.com - 2026-04-21 13:46:15

The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com - 2026-04-21 10:57:16

Fortis Capital Advisors LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,485 shares of the company's stock, valued at approximately $1,345,000. Several other institutional investors and hedge funds

defenseworld.net - 2026-04-20 04:16:53